US2023218655A1PendingUtilityA1

Cancer treatments

65
Assignee: NuCana plcPriority: Jun 1, 2016Filed: Aug 1, 2022Published: Jul 13, 2023
Est. expiryJun 1, 2036(~9.9 yrs left)· nominal 20-yr term from priority
Inventors:Hugh GriffithChris PepperChris Mcguigan
A61K 31/7064A61K 31/7076A61K 31/7068A61K 31/7072A61P 35/00A61P 35/02A61K 31/675A61P 35/04A61K 45/06C07K 16/22
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are medical uses and methods for targeting cancer stem cells employing ProTide compounds, particularly in the prevention or treatment of cancer. The ProTide may be other than one selected from the group consisting of: NUC-1031; a ProTide derived from cordycepin; and a ProTide derived from 8-chloroadenosine. The medical uses and methods for targeting cancer stem cells are particularly useful in the treatment of relapsed or refractory cancer in human patients. Also provided are methods of selecting patients who will benefit from prevention or treatment of cancer through the medical uses or methods of treatment of the invention.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method of killing cancer stem cells in a patient with cancer, comprising administering to the patient in need thereof an effective amount of a compound of the formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof in combination with a chemotherapeutic agent, wherein the cancer is selected from the group consisting of lung cancer, liver cancer, breast cancer, head and neck cancer, neuroblastoma, thyroid carcinoma, skin cancer, oral squamous cell carcinoma, urinary bladder cancer, pancreatic cancer, colon cancer, colorectal cancer and gynecological cancer. 
       
     
     
         2 . The method of  claim 1 , wherein the chemotherapeutic agent is an inhibitor of the VEGF pathway. 
     
     
         3 . The method of  claim 2 , wherein the inhibitor of the VEGF pathway is bevacizumab. 
     
     
         4 . The method of  claim 1 , wherein the chemotherapeutic agent is a mitotic inhibitor. 
     
     
         5 . The method of  claim 1 , wherein the chemotherapeutic agent is a monoclonal antibody. 
     
     
         6 . The method of  claim 5 , wherein the monoclonal antibody is a passive or active immunotherapy. 
     
     
         7 . The method of  claim 1 , wherein the chemotherapeutic agent is a topoisomerase inhibitor. 
     
     
         8 . The method of  claim 1 , wherein the chemotherapeutic agent is a metallic agent. 
     
     
         9 . The method of  claim 1 , wherein the cancer is relapsed or refractory. 
     
     
         10 . The method of  claim 9 , wherein the cancer is relapsed. 
     
     
         11 . The method of  claim 9 , wherein the cancer is refractory. 
     
     
         12 . The method according to  claim 1 , wherein the compound is administered intravenously. 
     
     
         13 . The method of  claim 1  wherein the cancer is colorectal cancer. 
     
     
         14 . The method of  claim 1 , wherein the cancer is lung cancer. 
     
     
         15 . The method of  claim 1 , wherein the compound and chemotherapeutic agent are administered at the same time. 
     
     
         16 . The method of  claim 1 , wherein the compound and chemotherapeutic agent are administered at the different times. 
     
     
         17 . The method of  claim 16 , wherein the compound is administered prior to the chemotherapeutic agent. 
     
     
         18 . The method of  claim 15 , wherein the compound is administered after the chemotherapeutic agent.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.